Bruce Nhu T, Neil William P, Zivin Justin A
San Diego VA Healthcare System, Neurology Service (127), 3350 La Jolla Village Drive, San Diego, CA, 92161, USA.
Curr Treat Options Cardiovasc Med. 2011 Jun;13(3):233-9. doi: 10.1007/s11936-011-0122-0.
Intravenous alteplase or tissue plasminogen activator (tPA) has been the standard of care with proven efficacy for acute ischemic stroke for over a decade. Despite this, only a small fraction of potentially eligible stroke patients receive this medication. There seems to be a fear among practitioners of legal repercussions as a result of an increased risk of intracerebral hemorrhage due to tPA. This review of legal cases involving tPA will show that instead, physicians are often found liable as a result of not treating with tPA.
静脉注射阿替普酶或组织纤溶酶原激活剂（tPA）十多年来一直是急性缺血性卒中经证实有效的标准治疗方法。尽管如此，只有一小部分可能符合条件的卒中患者接受这种药物治疗。由于tPA导致脑出血风险增加，从业者似乎担心会有法律后果。对涉及tPA的法律案件的审查将表明，相反，医生往往因未使用tPA进行治疗而被认定有责任。
